Viewing Study NCT07190300


Ignite Creation Date: 2025-12-26 @ 12:16 PM
Ignite Modification Date: 2025-12-31 @ 5:54 PM
Study NCT ID: NCT07190300
Status: RECRUITING
Last Update Posted: 2025-12-02
First Post: 2025-09-16
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Sponsor: Novartis Pharmaceuticals
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module